Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 15/20 | 0.61 |
| ▸ | CA1 | P00915 | 14/20 | 0.61 |
| ▸ | CA2 | P00918 | 14/20 | 0.61 |
| ▸ | CA12 | O43570 | 6/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.59 |
| ▸ | CA7 | P43166 | 2/20 | 0.59 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.56 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.52 |
| ▸ | BTK | Q06187 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17245254 | 0.91 | CA1 (0.64) | CA9CA1CA2CA12CA14 | |
| SCHEMBL19455756 | 0.91 | CA1 (0.64) | CA9CA1CA2CA12CA14 | |
| SCHEMBL14754541 | 0.88 | CA1 (0.67) | CA9CA1CA2CA12CA14 | |
| SCHEMBL18737255 | 0.88 | CA9 (0.67) | CA9CA1CA2CA12CA14 | |
| SCHEMBL18737217 | 0.88 | CA9 (0.65) | CA9CA1CA2CA12CA14 | |
| SCHEMBL21183301 | 0.88 | CA1 (0.70) | CA9CA1CA2CA12CA14 | |
| SCHEMBL21282083 | 0.88 | CA1 (0.70) | CA9CA1CA2CA12CA14 | |
| SCHEMBL17245251 | 0.88 | CA1 (0.70) | CA9CA1CA2CA12CA14 | |
| SCHEMBL22203877 | 0.86 | CA1 (0.66) | CA9CA1CA2CA12CA14 | |
| SCHEMBL15958213 | 0.85 | CA9 (0.70) | CA9CA1CA2CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759480-B2 | Compositions and methods for CAR T cell therapy | ENDOCYTE, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20210346431-A1 | SEQUENCING METHOD FOR CAR T CELL THERAPY | Seattle Children's Hospital (dba Seattle Children's Research Institute) | 2021-11-11 | — | — | US | disclosed |
| US-20200405760-A1 | COMPOSITIONS AND METHODS FOR CAR T CELL THERAPY | ENDOCYTE, INC. | 2020-12-31 | — | — | US | disclosed |
| US-20160326086-A1 | 4-HYDROXYBUTYRIC ACID ANALOGS | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11759480-B2 | Compositions and methods for CAR T cell therapy | CD47, PBK, GZMB | CA9 542/4885CA1 1175/4885CA2 3139/4885 |
| US-20160326086-A1 | 4-HYDROXYBUTYRIC ACID ANALOGS | HCRTR2, HCRTR1, HTR2B | CA9 1670/4885CA1 1490/4885CA2 351/4885 |
| US-20210346431-A1 | SEQUENCING METHOD FOR CAR T CELL THERAPY | CD47, MCTS1, GZMB | CA9 567/4885CA1 2463/4885CA2 3547/4885 |
| US-20200405760-A1 | COMPOSITIONS AND METHODS FOR CAR T CELL THERAPY | CD47, PBK, GZMB | CA9 542/4885CA1 1175/4885CA2 3139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.